In December 2011, our scientists presented multiple posters and presentations at the 53rd American Society of Hematology (ASH) Annual Meeting and Exposition held in San Diego, CA.  We shared data from two programs within our “Alnylam 5x15” product pipeline, including pre-clinical data from  ALN-APC, an RNAi therapeutic targeting protein C for the treatment of hemophilia,... [spotlight-link icon="presentation" href="" type="(680 KB PPT)"]View the refractory anemia presentation[/spotlight-link] [spotlight-link icon="presentation" href="" type="(1.88 MB PDF)"]View the hemophilia poster[/spotlight-link] [spotlight-link icon="presentation" href="" type="(112 KB PDF)"]View the beta-thalassemia poster [/spotlight-link] [spotlight-link icon="presentation" href="" type="(435 KB PDF)"]View the erythropoiesis poster[/spotlight-link] [spotlight-link icon="release" href="" type=" "]Read our press release[/spotlight-link]

We have launched our fourth program as part of our Alnylam 5x15 product development strategy.  ALN-APC is an RNAi therapeutic for the treatment of hemophilia, and as with our other Alnylam 5x15 programs, targets protein C, a genetically defined target, and will utilize Alnylam’s existing delivery platform. [spotlight-link icon="release" href="" type=" "]Read our press release[/spotlight-link] [spotlight-link icon="podcast" href="" type="(13.3MB mp3)"]Listen to our CMO discuss the hemophilia program[/spotlight-link] [spotlight-link icon="presentation" href= type="(1.5MB PPT)"]View the slides [/spotlight-link]


Receive news and updates on the work at Alnylam that affects you most.